Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/29/2026, 12:00:00 AM
European Commission authorized expanded label for VENCLYXTO (venetoclax) for untreated CLL on 2026-05-29. Low importance as label expansions typically result in moderate price movement.
Korean Translation
2026년 5월 29일, 유럽연합 집행위원회가 만성 림프구성 백혈병(CLL) 치료를 위한 벤클릭스토(베네토클락스)의 라벨 확대를 승인함. 적응증 확대에 따른 통상적인 시장 반응을 고려하여 중요도를 낮게 평가함.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM